Biomarkers

Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

BACKGROUND

Ceramides have garnered considerable attention as pro-aging bioactive lipids implicated in both metabolic dysfunction and musculoskeletal decline. Among these, C18:0 and C24:1 ceramides may play a role in the pathophysiology of sarcopenia, a key manifestation of age-related deterioration. However, their...

🗓️ 2026-05-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

An exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.

🗓️ 2026-04-06
📰 Publication: Aging Clinical And Experimental Research
Read MoreAn exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.

Circulating Inflammatory and Mitochondrial Biomarkers Associated with Cachexia in Advanced Non-Small Cell Lung Cancer.

Background: Cancer-associated cachexia is a multifactorial metabolic syndrome characterized by progressive skeletal muscle and/or adipose tissue loss and affects approximately 40% of patients with non-small cell lung cancer (NSCLC). However, reliable circulating biomarkers for early detection and risk stratification remain...

🗓️ 2026-02-27
Read MoreCirculating Inflammatory and Mitochondrial Biomarkers Associated with Cachexia in Advanced Non-Small Cell Lung Cancer.

Role of Peptides in Skeletal Muscle Wasting: A Scoping Review.

BACKGROUND

Systemic muscle wasting is a prevalent condition that predicts adverse health outcomes in aging and disease. Despite its clinical relevance, the development of predictive biomarkers and effective pharmacological therapies remains limited. Peptides have recently gained attention for their diverse bioactive...

🗓️ 2025-11-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRole of Peptides in Skeletal Muscle Wasting: A Scoping Review.

Integrating genetics and transcriptome analyses identify potential biomarkers and immune interactions in metabolic syndrome-related sarcopenia.

BACKGROUND

Increasing evidence has indicated that metabolic syndrome (MetS) exists in a close link with sarcopenia; however, the potential mechanism and biomarkers between them remain uninvestigated. This study leverages integrative genetics and transcriptome to identify potential biomarkers and immune interactions in...

🗓️ 2025-11-06
Read MoreIntegrating genetics and transcriptome analyses identify potential biomarkers and immune interactions in metabolic syndrome-related sarcopenia.

Cachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival.

Introduction: Cancer cachexia is associated with systemic inflammation and metabolic derangement, leading to muscle atrophy, which affects over 80% of pancreatic cancer patients, the highest rate among all malignancies, negatively impacting quality of life and significantly reducing survival rate. Malnutrition,...

🗓️ 2025-09-25
Read MoreCachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival.

Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.

Colorectal cancer (CRC) is a leading cause of cancer-related deaths and obesity is a known risk factor for its development and poor prognosis. Adipose tissue (AT) actively contributes to CRC progression and cachexia. Here, we investigated molecular crosstalk between tumor...

🗓️ 2025-10-06
📰 Publication: Cell Death & Disease
Read MoreAdipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.

Muscle-Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I-Lan Longitudinal Aging Study.

Muscle-specific strength (MSS), defined as grip strength normalized to arm muscle mass, may better reflect muscle efficiency than grip strength. Despite its potential utility in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia-related outcomes remain limited. This...

🗓️ 2025-10-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle-Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I-Lan Longitudinal Aging Study.

Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

AI-driven automated body composition analysis (BCA) may provide quantitative prognostic biomarkers derived from routine staging CTs. This two-centre study evaluates the prognostic value of these volumetric markers for overall survival in lung cancer patients. Lung cancer cohorts from Hospital A...

🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreExploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

Elevated Serum Gamma-Glutamyl Transferase as a Risk Factor for Frailty in Older Men: A Nationwide Population-Based Study.

Oxidative stress is a key driver of accelerated ageing, and gamma-glutamyl transferase (GGT), an essential enzyme involved in the metabolism of glutathione, a major antioxidant, plays a pivotal role in the generation of free radical species. This study aimed to...

🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Serum Gamma-Glutamyl Transferase as a Risk Factor for Frailty in Older Men: A Nationwide Population-Based Study.

Circulating miR-144-3p as a Novel Independent Biomarker Associated With Low Muscle Strength Among Older Adults.

Low muscle strength, a key component of sarcopenia, is significant in the development of adverse health outcomes among older adults. MicroRNAs (miRNAs) have been implicated in mechanisms of sarcopenia; however, their specific functions in sarcopenia components, particularly low muscle strength,...

🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCirculating miR-144-3p as a Novel Independent Biomarker Associated With Low Muscle Strength Among Older Adults.

GDF15: from biomarker to target in cancer cachexia.

Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...

🗓️ 2025-07-09
📰 Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.

Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine.

Sarcopenia, a progressive decline in skeletal muscle mass and function, has emerged as a critical geriatric syndrome affecting 10-40% of older adults, contributing to increased disability and mortality. This comprehensive review evaluates evidence-based strategies for sarcopenia management, from established interventions...

🗓️ 2025-06-11
📰 Publication: Clinical Nutrition
Read MoreTherapeutic advances in sarcopenia management: From traditional interventions to personalized medicine.

Association of Alzheimer's Disease Blood Biomarkers With Sarcopenia Incidence and Progression: A 12-Year Population-Based Study.

Sarcopenia is a complex and multifactorial condition, and recent studies have explored the role of neurological markers in its diagnosis and prediction. Although associations have been identified between reduced muscle strength, slow walking speed and elevated neurofilament levels (NfL), long-term...

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAssociation of Alzheimer's Disease Blood Biomarkers With Sarcopenia Incidence and Progression: A 12-Year Population-Based Study.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!